| scholarly article | Q13442814 |
| editorial | Q871232 |
| P50 | author | Pasi A Jänne | Q74766165 |
| P2093 | author name string | Pasi A Jänne | |
| Amanda J Redig | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 975-977 | |
| P577 | publication date | 2015-02-09 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Basket trials and the evolution of clinical trial design in an era of genomic medicine | |
| P478 | volume | 33 |
| Q52676785 | A Bayesian basket trial design using a calibrated Bayesian hierarchical model. |
| Q59134800 | A Pilot Prospective Study of Refractory Solid Tumor Patients for NGS-Based Targeted Anticancer Therapy |
| Q41023790 | A novel molecular diagnostics platform for somatic and germline precision oncology |
| Q43609891 | A three gene immunohistochemical panel serves as an adjunct to clinical staging of patients with head and neck cancer |
| Q54425017 | Adapting to stress - chaperome networks in cancer |
| Q99557458 | Adaptive trial designs for spinal cord injury clinical trials directed to the central nervous system |
| Q55103799 | Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials. |
| Q41439410 | Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency |
| Q47186490 | Bioinformatics for precision oncology |
| Q47377237 | Biomarkers: Delivering on the expectation of molecularly driven, quantitative health |
| Q26771396 | Bridging academic science and clinical research in the search for novel targeted anti-cancer agents |
| Q26741009 | Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives |
| Q33907581 | Cardiovascular Late Effects and Exercise Treatment in Breast Cancer: Current Evidence and Future Directions |
| Q92132872 | Challenges and approaches to implementing master/basket trials in oncology |
| Q38965980 | Clinical Trials and the Role of the Oncology Clinical Trials Nurse |
| Q38849191 | Clinical development of new drug-radiotherapy combinations |
| Q37310971 | Combined integrated protocol/basket trial design for a first-in-human trial |
| Q37065325 | Core Concept: Basket trial approach capitalizes on the molecular mechanisms of tumors |
| Q37555973 | Current status and perspectives of interventional clinical trials for glioblastoma - analysis of ClinicalTrials.gov |
| Q38888022 | Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer |
| Q41783629 | Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors |
| Q90178658 | Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors? |
| Q36372293 | ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up |
| Q47893147 | Evidence-Based Precision Oncology with the Cancer Targetome. |
| Q48292408 | Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets |
| Q92624383 | Feasibility of genomic profiling with next-generation sequencing using specimens obtained by image-guided percutaneous needle biopsy |
| Q38830137 | From drug response profiling to target addiction scoring in cancer cell models |
| Q33823065 | Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine. |
| Q26852049 | Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies |
| Q26751655 | Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy |
| Q48877738 | Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). |
| Q96302702 | Histology-agnostic drug development - considering issues beyond the tissue |
| Q36902033 | Identification of a Novel Pathogenic Germline KDR Variant in Melanoma. |
| Q92503954 | Immunotherapy in breast cancer |
| Q37059799 | Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials |
| Q42331905 | Improving the efficiency of trials using innovative pilot designs: the next phase in the conduct and reporting of pilot and feasibility studies |
| Q64041411 | Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation |
| Q57124868 | Master protocol trials in oncology: Review and new trial designs |
| Q47835092 | Model-Informed Drug Development for Malaria Therapeutics |
| Q88917856 | Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design |
| Q38947183 | New and emerging targeted treatments in advanced non-small-cell lung cancer. |
| Q64113631 | New clinical trial designs in the era of precision medicine |
| Q36174832 | Next-Generation Sequencing to Guide Clinical Trials |
| Q47129835 | Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care? |
| Q26801946 | Next-generation sequencing to guide cancer therapy |
| Q64039749 | Optimizing Precision Medicine for Public Health |
| Q38685850 | Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study |
| Q38822454 | Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer. |
| Q38840660 | Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. |
| Q37290101 | Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways |
| Q50218019 | Personalized oncology |
| Q26780388 | Perspectives on research activity in the USA on Cancer Precision Medicine |
| Q47701712 | Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer |
| Q37163870 | Precision Oncology Framework for Investigation of Exercise As Treatment for Cancer |
| Q38838757 | Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment |
| Q45943066 | Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours. |
| Q42344274 | Precision medicine in lung cancer: the battle continues |
| Q26767798 | Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations |
| Q91214765 | Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations |
| Q36803785 | Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988-2011: a population-based study |
| Q52566012 | Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities. |
| Q38786662 | Radiation oncology in the era of precision medicine. |
| Q38665620 | Radiogenomics and radiotherapy response modeling. |
| Q26747276 | Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC |
| Q39012781 | Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making? |
| Q55379483 | Sarcoma-The standard-bearer in cancer discovery. |
| Q92094957 | Secretome profiling identifies neuron-derived neurotrophic factor as a tumor-suppressive factor in lung cancer |
| Q55179580 | Signature program: a platform of basket trials. |
| Q96644193 | Single-Arm Clinical Trials as Pivotal Evidence for Cancer Drug Approval: a Retrospective Cohort Study of Centralised European Marketing Authorizations between 2010-2019 |
| Q58592517 | Statistical challenges posed by uncontrolled master protocols: sensitivity analysis of the Vemurafenib study |
| Q39126105 | Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples |
| Q39181808 | Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation |
| Q36309864 | Systematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data. |
| Q59132270 | Systemic immune-inflammation index, SII, for prognosis of elderly patients with newly diagnosed tumors |
| Q93270320 | TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials |
| Q28083446 | Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK |
| Q42204343 | The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy. |
| Q92830541 | The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers |
| Q43134289 | The Signature Program: Bringing the Protocol to the Patient |
| Q36635960 | The VA Point-of-Care Precision Oncology Program: Balancing Access with Rapid Learning in Molecular Cancer Medicine |
| Q36943659 | The impact of genomics on health outcomes, quality, and safety. |
| Q36296335 | Tissue-specific tumorigenesis: context matters |
| Q33769821 | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease |
| Q49184931 | Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors. |
| Q47207132 | TumorFusions: an integrative resource for cancer-associated transcript fusions. |
| Q31115480 | Use of big data in drug development for precision medicine |
| Q31138564 | Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases |
| Q38937135 | Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology |
Search more.